Anthos Therapeutics Overview
- Year Founded
-
2019
- Status
-
Acquired/Merged
- Employees
-
41
- Latest Deal Type
-
M&A
- Financing Rounds
-
3
Anthos Therapeutics General Information
Description
Operator of a clinical-stage biopharmaceutical company focused on the development and commercialization of genetically and pharmacologically validated innovative therapies to advance care for people living with cardiovascular and metabolic (CVM) diseases. The company's therapies are directed at Factor XI and XIa, a key component of the intrinsic coagulation pathway that represents an anti-thrombotic investigational therapy, thereby enabling healthcare professionals to prevent multiple thrombotic diseases with minimal or no bleeding risk within a new, long-acting treatment paradigm and providing major advantages over the conventional standards of care.
Contact Information
Website
www.anthostherapeutics.com(Operating Subsidiary)
Corporate Office
- 1 Health Plaza
- East Hanover, NJ 07936
- United States
Corporate Office
- 1 Health Plaza
- East Hanover, NJ 07936
- United States
Anthos Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Anthos Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
News about Anthos Therapeutics
Dive into recent articles by PitchBook offering invaluable insights and context.
Anthos Therapeutics Patents
Anthos Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2023287807-A1 | Combination therapies with an anti-factor xi/factor xia antibody | Pending | 24-Jun-2022 | ||
| EP-4543434-A2 | Combination therapies with an anti-factor xi/factor xia antibody | Pending | 24-Jun-2022 | ||
| EP-4543434-A4 | Combination therapies with an anti-factor xi/factor xia antibody | Pending | 24-Jun-2022 | ||
| US-20260232796-A1 | Combination therapies with an anti-factor xi/factor xia antibody | Pending | 24-Jun-2022 | ||
| WO-2023250463-A2 | Combination therapies with an anti-factor xi/factor xia antibody | Inactive | 24-Jun-2022 | C07K16/36 |
Anthos Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Anthos Therapeutics Former Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Anthos Therapeutics FAQs
-
When was Anthos Therapeutics founded?
Anthos Therapeutics was founded in 2019.
-
Where is Anthos Therapeutics headquartered?
Anthos Therapeutics is headquartered in East Hanover, NJ.
-
What is the size of Anthos Therapeutics?
Anthos Therapeutics has 41 total employees.
-
What industry is Anthos Therapeutics in?
Anthos Therapeutics’s primary industry is Drug Discovery.
-
Is Anthos Therapeutics a private or public company?
Anthos Therapeutics is a Private company.
-
What is the current valuation of Anthos Therapeutics?
The current valuation of Anthos Therapeutics is .
-
What is Anthos Therapeutics’s current revenue?
The current revenue for Anthos Therapeutics is .
-
Who are Anthos Therapeutics’s investors?
Blackstone Life Sciences, Nan Fung Life Sciences, Novo Holdings, and Pivotal bioVenture Partners have invested in Anthos Therapeutics.
-
When was Anthos Therapeutics acquired?
Anthos Therapeutics was acquired on 03-Apr-2025.
-
Who acquired Anthos Therapeutics?
Anthos Therapeutics was acquired by Novartis.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
